With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.
T = Trends for a Stock’s MovementCorning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.
Corning on Tuesday announced its results for the fourth quarter and full year of 2013.�Core earnings per share were 29 cents, an increase of 4 percent over last year�� fourth quarter and better than expected. GAAP earnings per share were 30 cents.�Core sales were $2 billion, a 2 percent decline from the comparable period last year.��013 was a very successful year for Corning,��Wendell P. Weeks, chairman, chief executive officer, and president, said in the earnings report. ��e achieved the company�� primary performance goal of restoring earnings growth. This was accomplished by regaining positive momentum in our LCD business and growing the earnings in our other segments. We also delivered on our commitment to enhance shareholder value by increasing the cash dividend and executing more than $1.5 billion in share repurchases. The company�� performance was recognized by a 41% improvement in the year�� share price, a result with which we are delighted.��/p>
Best Industrial Disributor Companies To Watch For 2015: ARC Document Solutions Inc (ARC)
ARC Document Solutions, Inc., formerly American Reprographics Company, provides specialized document solutions to businesses of all types, with a focus on the non-residential segment of the architecture, engineering and construction (AEC) industry. The Company offers reprographic services, as well as managed print services, digital color printing, and document management technology products and services. It also has operations in Canada, China, India and the United Kingdom. It is a document solutions company serving the AEC industry that provides document management services through a combination of local service facilities in more than 40 states, 12 digital color service centers, online channels, including Web-based applications, and software. The Company conducts its operations through a wholly owned subsidiary, American Reprographics Company, L.L.C. and its subsidiaries.
The Company offers three general categories of service: Reprographics Services, Facilities Management, and Equipment and Supplies. Reprographics Services sales include operational activities, such as document management services, document logistics, large- and small-format print-on-demand services in color and black and white, and digital document management services. Facilities Management sales are primarily composed of onsite services, where it provides document production equipment, technology solutions and sometimes staff to its customers in their offices. These services include both traditional reprographics services focused on large-format printing, as well as managed print services (MPS). Under an MPS contract, it supplies, maintains and manages a customer�� entire print networks, including office printing equipment, on an outsourced basis. Equipment and Supplies sales involve the resale of printing and imaging equipment and supplies from a variety of suppliers.
As of December 31, 2011, the Company operated 220 reprographics service centers, of which 199 were in the United States, seven were in ! Canada, 11 were in China, two were in India and one in London, England. It also occupied a technology center in Silicon Valley, California, a software programming facility in Kolkata, India, as well as other facilities, including its offices located in Walnut Creek, California. The Company�� products and services are available from any of ARC�� 220 service centers worldwide. The Company supplies reprographics services to project architects, engineers, general contractors and others. In addition to the AEC industry, ARS also provides document management and printing services to the retail, aerospace, technology, entertainment, and healthcare industries, among others.
The Company competes with Oce, Xerox, Canon, Konica Minolta, Ricoh and Sharp.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on ARC Document Solutions (NYSE: ARC ) , whose recent revenue and earnings are plotted below.
Hot Life Sciences Stocks For 2014: Revlon Inc.(REV)
Revlon, Inc., through its subsidiaries, engages in manufacturing, marketing, and selling cosmetics, women?s hair color, beauty tools, anti-perspirant deodorants, fragrances, skincare, and other beauty care products worldwide. The company?s cosmetics include face makeup products, including foundation, powder, blush, concealers, bronzers, and finishers; lip makeup products comprising lipsticks, lip glosses, and lip liners; eye makeup products consisting of mascaras, eyeliners, eye shadows, and brow products; nail color and nail care products, such as enamels, treatments, and cuticle preparations; and face and eye makeup removers. Its beauty tools comprise nail, eye, and pedicure grooming tools, such as clippers, scissors, files, tweezers, eye lash curlers, and makeup brushes; and fragrances consist of perfumes, eau de toilettes, colognes, and body sprays. The company markets its products primarily under Revlon, Revlon ColorStay, Revlon Super Lustrous, Revlon Age Defying, A lmay Intense i-Color, Almay Smart Shade, Revlon ColorSilk, Mitchum, Charlie, Jean Nate, Ultima II, and Gatineau names. Revlon, Inc. sells its products through sales representatives and independent distributors to mass volume retailers, chain drug stores, chemist shops, hypermarkets, general merchandise stores, department stores; other specialty stores, such as perfumeries; and to the United States military exchanges and commissaries. It also licenses its brand names to third parties for the manufacture and sale of beauty-related products and accessories. The company was founded in 1932 and is based in New York, New York. Revlon, Inc. is a subsidiary of MacAndrews & Forbes Holdings Inc.
Advisors' Opinion:- [By Eric Volkman]
Revlon (NYSE: REV ) will need to have a serious discussion with its headhunters. The company revealed in an SEC filing that Executive Vice President and CFO Steven Berns has tendered his resignation. He has done so in order to take up the same positions at privately held media conglomerate Tribune Company.�
Hot Life Sciences Stocks For 2014: Stereotaxis Inc.(STXS)
Stereotaxis, Inc. designs, manufactures, and markets cardiology instrument control systems for use in a hospital?s interventional surgical suite or interventional lab for the treatment of arrhythmias and coronary artery diseases in the United States and internationally. The company provides Niobe system, which includes Niobe Magnetic Navigation System that navigates catheters, guidewires, and other delivery devices through complex paths in the blood vessels and chambers of the heart to carry out treatment; Navigant, a user interface or physician control center, which physicians use to visualize and track procedures and to provide instrument control commands that govern the motion of the working tip of the catheter, guidewire, or other interventional device; Cardiodrive, a catheter advancement system to remotely advance and retract the catheter in the patient?s heart. It also offers Odyssey enterprise solutions, which provides information solutions to manage, control, rec ord, and share procedures across networks; acquires remote view of the lab capturing synchronized procedure data for review of important events during cases; and review recorded cases and create snapshots following procedures for clinical reporting, auditing, and presentation. In addition, the company provides disposable interventional devices comprising automated catheters, coronary guidewires, and navigation and ablation systems. It markets its products through its direct sales force, distributors, and sales agents. The company was founded in 1990 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Bryan Murphy]
Look out Intuitive Surgical, Inc. (NASDAQ:ISRG), and step aside BioTelemetry Inc. (NASDAQ:BEAT). There's a new cardiac name in town, and its name is Stereotaxis Inc. (NASDAQ:STXS). This small company's stock is soaring today on the heels of encouraging news, though the prompt for the stock's strength has been brewing for quite some time. This nudge for STXS, however, may well mean it has a lot more potential than ISRG or BEAT do for the foreseeable future.
Hot Life Sciences Stocks For 2014: MFA Financial Inc (MFA)
MFA Financial, Inc., incorporated on July 24, 1997, is engaged in the business of investing, on a leveraged basis, in residential Agency mortgage-backed securities (MBS) and Non-Agency MBS. Its business objective is to generate net income for distribution to its stockholders resulting from the difference between the interest and other income it earn on its investments and the interest expense it pays on the borrowings, which it uses to finance its leveraged investments and its operating costs. Its operating policies require that at least 50% of its investment portfolio consist of ARM-MBS, which are either Agency MBS or rated in two rating categories by at least one of rating agency, such as Moody�� Investors Services, Inc., Standard & Poor�� Corporation (S&P) or Fitch, Inc. The remainder of its assets may consist of direct or indirect investments in other types of MBS and residential mortgage loans; other mortgage and real estate-related debt and equity; and other yield instruments.
The mortgages collateralizing the Company�� MBS portfolio are Hybrids, ARMs and 15-year fixed-rate mortgages. The Hybrids collateralizing its MBS typically have fixed-rate periods ranging from three to 10 years. Interest rates on the mortgage loans collateralizing its ARM-MBS reset based on specific index rates, which include London Interbank Offered Rate (LIBOR) or the one-year constant maturity treasury (CMT) rate. The mortgages collateralizing its ARM-MBS have interim and lifetime caps on interest rate adjustments. The Company�� Non-Agency MBS have been at discounts to face/par value.
Advisors' Opinion:- [By Rich Duprey]
After raising its payout last quarter by 10%,�residential mortgage-backed securities REIT�MFA Financial (NYSE: MFA ) announced today it was keeping its second-quarter dividend steady at $0.22 per share.
Hot Life Sciences Stocks For 2014: Nuveen Municipal High Income Opportunity Fund (NMZ)
Nuveen Municipal High Income Opportunity Fund (the Fund) is a closed-ended fund. The fund's primary investment objective is to provide high current income exempt from regular federal income tax. Its secondary investment objective is to seek attractive total return consistent with its primary objective. The fund invests in municipal securities that are exempt from federal income taxes. The fund invests at least 50% of its managed assets in municipal securities rated, at the time of investment, investment grade (Baa/BBB or better by S&P, Moody's, and Fitch) or, if they are unrated, are judged by the manager to be of comparable quality. The fund may invest up to 50% of its managed assets in municipal securities that, at the time of investment, are rated below investment grade quality or that are unrated but judged by the manager to be of comparable quality. The Fund�� investment advisor is Nuveen Fund Advisors, Inc. Advisors' Opinion:- [By Jon C. Ogg]
8. Municipal bonds outperform taxable bond counterparts – The move is predicted to be led by high-yield after serious outflows from municipal bond funds. Doll’s take: the pricing of municipal securities relative to taxable fixed income securities more than take that into account.
First Recommendation: Nuveen Municipal High Income Opportunity Fund (NYSEMKT: NMZ) as a high-yield closed-end fund municipal bond fund. The fund may invest up to 50% of its managed assets in municipal securities rated below investment grade quality, but no more than 5% of the managed assets may be invested in munis rated at or below B3/B-. Second recommendation: Market Vectors High-Yield Muni ETF (NYSEArca: HYD)9. Active managers outperform index funds – This stance is one which has been an ongoing issue for years and years with most managers underperforming benchmarks. Doll believes that active managers have a better chance to outperform when markets and sectors have less correlation.
Hot Life Sciences Stocks For 2014: Neenah Paper Inc. (NP)
Neenah Paper, Inc. produces technical products and fine papers worldwide. The company�s Technical Products segment provides filtration media for applications in automotive transportation; saturated and unsaturated crepe and flat paper tapes to manufacturers; lightweight abrasive paper for waterproof and dry sanding applications; wall covering substrates to converters serving commercial and consumer-do-it-yourself markets; label and tag products to pressure sensitive coaters; latex saturated and coated papers; premask, medical packaging, image transfer, and decorative components papers; and other products, such as clean room papers, durable printing papers, release papers, and furniture backers. Its Fine Paper segment manufactures and sells writing papers used for business and personal stationery, corporate identity packages, and related end-use applications; text and cover papers and envelopes used in corporate brochures, pocket folders, corporate annual reports, advertis ing inserts, direct mail, business cards, hang tags, scrapbooks, and various other uses; custom colors, paper finishes, and duplex/laminated papers; and bright papers used in direct mail, advertising inserts, scrapbooks, and marketing collateral applications. This segment also offers other specialty papers for various applications in wine labels and luxury packaging, as well as specialty paper products for enhanced image, such as translucent and art papers, papers for optical scanning, and other specialized applications. Neenah Paper, Inc. markets its products primarily under the JET-PRO, SofStretch, KIMDURA, MUNISING LP, PREVAIL, NEENAH, GESSNER, varitess, CLASSIC, CLASSIC CREST, ESSE ENVIRONMENT, ROYAL SUNDANCE, ASTROBRIGHTS, EXACT BRIGHTS, CAPITOL BOND, CRANE'S BOND, and CRANE'S LETTRA brands. The company sells its products through authorized paper distributors, converters, and direct sales. Neenah Paper, Inc. was founded in 2004 and is headquartered in Alpharetta, Georgi a.
Advisors' Opinion:- [By Rich Duprey]
Specialty-paper maker�Neenah Paper� (NYSE: NP ) �announced yesterday�its third-quarter dividend of $0.20 per share, a�33% increase over the $0.15 per-share payout made last quarter, and comes quickly on the heels of a 25% dividend hike it made with the first-quarter payout.
Hot Life Sciences Stocks For 2014: Portola Pharmaceuticals Inc (PTLA)
Portola Pharmaceuticals, Inc. (Portola), incorporated on September 2, 2003, is a biopharmaceutical company developing product candidates that have the potential to represent advances in the fields of thrombosis and hematology. The Company is advancing its three wholly owned programs using biomarker and genetic approaches.
Betrixaban
Portola's compound, betrixaban, is an oral, once-daily Factor Xa inhibitor being evaluated in the only biomarker-based Phase-III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Betrixaban's properties particularly suited to potentially demonstrate efficacy without increasing bleeding in this patient population.
Andexanet Alfa
Portola's second development candidate, andexanet alfa (PRT4445), has the potential to be a reversal agent to directly reverse the effects of Factor Xa inhibitors in patients who suffer a bleeding episode or who require emergency surgery. Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb and Pfizer (Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO [rivaroxaban]), and Daiichi Sankyo (Savaysa [edoxaban]), while retaining all decision-making and commercial rights to the program.
Cerdulatinib (PRT2070) and PRT2607
Portola's third wholly owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways - spleen tyrosine kinase (Syk) and janus kinase (JAK). It is being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations. Portola's fourth program is partnered with Biogen Idec and is focused on the development of PRT2607, a selective Syk inhibitor.
Advisors' Opinion:- [By Todd Campbell]
That leads me to Medivation (NASDAQ: MDVN ) , Ophthotech (NASDAQ: OPHT ) , and Portola (NASDAQ: PTLA ) , three companies with important therapies that may very well be destined to become top sellers.
No comments:
Post a Comment